View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Benoit Valleaux ... (+5)
  • Benoit Valleaux
  • Roland Pfaender
  • MBA
  • CFA
  • CCRA
Benoit Valleaux ... (+5)
  • Benoit Valleaux
  • Roland Pfaender
  • MBA
  • CFA
  • CCRA
Team Pharma
  • Team Pharma

ODDO : Les fondamentaux face à l’incertitude

Les déboires récents de quelques sociétés du secteur (déceptions de CagriSema de Novo, de l’anti-TIGIT de Roche ou investigations en Chine pour AZN) accompagnés de questionnements sur la politique US ont engendré un derating conduisant à une valorisation faciale attractive : PE 26e de 13.2x. Les publications annuelles des 6 large cap Pharma européennes ont été extrêmement rassurantes confirmant les attentes CT et LT du marché. Avec un BPA en croissance moyenne entre 2024 et 2028 de c10%, le PEG ...

Team Pharma
  • Team Pharma

ODDO : Fundamentals vs uncertainty

The recent setbacks for some sector companies (disappointments over Novo Nordisk’s Cagrisema and Roche’s anti-TIGIT or the investigations in China for AZN) along with question marks over US policy have generated a derating leading to a nominally attractive valuations: P/E 2026e of 13.2x. The full-year earnings reports of the six European large cap pharma companies were extremely reassuring, confirming short- and long-term market expectations. With average expected EPS growth between 2024 and 202...

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

EU Pharma - 5 Reasons for Further Re-rating (Thematic, 42pgs)

Given the macro backdrop & our evidence in this note that Pharma can sustain faster than expected growth for the next decade, we believe investors should add to their Pharma positions. 2025 is the biggest year for pipeline readouts in recent history and we expect this to catalyse a re-rating. We show that 1) Pipelines are very robust, 2) The market underestimates the size of the “monster” blockbusters that account for 14% of all drugs, 3) 15% of 2030 sales are “generic resistant” due to the moda...

AstraZeneca PLC: Update following upgrade to A1

Our credit view of this issuer reflects its broad product portfolio and its rapid growth in product sales with favourable operating leverage.

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

AZN - Innovation Premium Warranted (BUY, TP £150 [£120], 14pgs)

Our new deep-dive on the P2 pipeline shows that AZN can sustain 6% CAGR sales growth to 2030 despite a number of LOE’s and as a result, we believe AZN warrants a significant innovation premium. We assume a 25% success rate for the P2 pipeline despite AZN historically delivering 30%. Moreover, there are a multitude of catalysts this year that will likely de-risk the L-T growth profile & drive significant cons. upgrades. Our analysis of the baxdrostat opportunity shows that consensus forecasts app...

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Morten Larsen
Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Morten Larsen
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Morten Larsen
Baptiste Salaville ... (+3)
  • Baptiste Salaville
  • Bruno Cavalier
  • Jerôme Bodin
CON CONTINENTAL AKTIENGESELLSCHAFT
FME FRESENIUS MEDICAL CARE AG
LHA DEUTSCHE LUFTHANSA AKTIENGESELLSCHAFT
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
1COV COVESTRO AG
FRA FRAPORT AG
TKA THYSSENKRUPP AG
WCH WACKER CHEMIE AG
ADS ADIDAS AG
G1A GEA GROUP AG
SLB.N SCHLUMBERGER NV
MC LVMH MOET HENNESSY LOUIS VUITTON SE
ROG ROCHE HOLDING LTD
MTX MTU AERO ENGINES AG
CBK COMMERZBANK AG
HO THALES SA
NOVN NOVARTIS AG
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
DAI DAIMLER AG
GBF BILFINGER SE
RHM RHEINMETALL AG
LXS LANXESS AG
GXI GERRESHEIMER AG
EL ESSILORLUXOTTICA SA
KCO KLOECKNER & CO SE
PSM PROSIEBENSAT.1 MEDIA SE
BRBY BURBERRY GROUP PLC
MRK MERCK KGAA
KER KERING SA
BOSS HUGO BOSS AG
SDF K+S AG
NOEJ NORMA GROUP SE
BAS BASF SE
SAN SANOFI
BAYN BAYER AG
VOW3 VOLKSWAGEN AG PREF
HEN3 HENKEL AG & CO. KGAA PREF
DTE DEUTSCHE TELEKOM AG
SY1 SYMRISE AG
01913 PRADA S.P.A.
DEZ DEUTZ AG
AIXA AIXTRON SE
KRN KRONES AG
NEM NEMETSCHEK SE
SAX STROEER SE & CO. KGAA
EVK EVONIK INDUSTRIES AG
KGX KION GROUP AG
MONC MONCLER SPA
BNR BRENNTAG SE
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
JUN3 JUNGHEINRICH AG PREF
AZN ASTRAZENECA PLC
DUE DURR AG
JST JOST WERKE AG
SHL SIEMENS HEALTHINEERS AG
S92 SMA SOLAR TECHNOLOGY AG
JEN JENOPTIK AG
KBX KNORR-BREMSE AG
HAG HENSOLDT AG
STLA STELLANTIS N.V.
FPE3 FUCHS PETROLUB SE
DTG DAIMLER TRUCK
GSK GSK PLC
STM STABILUS SE
TUI TUI AG
NOVO B NOVO NORDISK A/S
SCHOTT PHARMA AG
R3NK RENK GROUP AG
AGN AEGON N.V.
QGEN QIAGEN N.V.
CVC CVC CAPITAL PARTNERS PLC
SHA SCHAEFFLER AG
Baptiste Salaville ... (+3)
  • Baptiste Salaville
  • Bruno Cavalier
  • Jerôme Bodin
CON CONTINENTAL AKTIENGESELLSCHAFT
FME FRESENIUS MEDICAL CARE AG
LHA DEUTSCHE LUFTHANSA AKTIENGESELLSCHAFT
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
1COV COVESTRO AG
FRA FRAPORT AG
TKA THYSSENKRUPP AG
WCH WACKER CHEMIE AG
ADS ADIDAS AG
G1A GEA GROUP AG
SLB.N SCHLUMBERGER NV
MC LVMH MOET HENNESSY LOUIS VUITTON SE
ROG ROCHE HOLDING LTD
MTX MTU AERO ENGINES AG
CBK COMMERZBANK AG
HO THALES SA
NOVN NOVARTIS AG
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
DAI DAIMLER AG
GBF BILFINGER SE
RHM RHEINMETALL AG
LXS LANXESS AG
GXI GERRESHEIMER AG
EL ESSILORLUXOTTICA SA
KCO KLOECKNER & CO SE
PSM PROSIEBENSAT.1 MEDIA SE
BRBY BURBERRY GROUP PLC
MRK MERCK KGAA
KER KERING SA
BOSS HUGO BOSS AG
SDF K+S AG
NOEJ NORMA GROUP SE
BAS BASF SE
SAN SANOFI
BAYN BAYER AG
VOW3 VOLKSWAGEN AG PREF
HEN3 HENKEL AG & CO. KGAA PREF
DTE DEUTSCHE TELEKOM AG
SY1 SYMRISE AG
01913 PRADA S.P.A.
DEZ DEUTZ AG
AIXA AIXTRON SE
KRN KRONES AG
NEM NEMETSCHEK SE
SAX STROEER SE & CO. KGAA
EVK EVONIK INDUSTRIES AG
KGX KION GROUP AG
MONC MONCLER SPA
BNR BRENNTAG SE
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
JUN3 JUNGHEINRICH AG PREF
AZN ASTRAZENECA PLC
DUE DURR AG
JST JOST WERKE AG
SHL SIEMENS HEALTHINEERS AG
S92 SMA SOLAR TECHNOLOGY AG
JEN JENOPTIK AG
KBX KNORR-BREMSE AG
HAG HENSOLDT AG
STLA STELLANTIS N.V.
FPE3 FUCHS PETROLUB SE
DTG DAIMLER TRUCK
GSK GSK PLC
STM STABILUS SE
TUI TUI AG
NOVO B NOVO NORDISK A/S
SCHOTT PHARMA AG
R3NK RENK GROUP AG
AGN AEGON N.V.
QGEN QIAGEN N.V.
CVC CVC CAPITAL PARTNERS PLC
SHA SCHAEFFLER AG
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch